WDM(SH:600055) Sou Hu Cai Jing·2026-01-31 20:23Core Viewpoint - WanDong Medical (600055) is facing a significant financial downturn, with projected net losses for 2025, primarily due to increased competition and strategic investments in R&D and international markets [1][3]. Financial Performance - WanDong Medical anticipates a net profit loss of between 199 million to 257 million yuan for the year 2025, marking a shift from profit to loss compared to the previous year [1][3]. - The expected loss in net profit is attributed to participation in medical device procurement, which has led to a decrease in gross margin, alongside increased investments in research and development and overseas market expansion [1]. Company Announcements - On January 26, 2026, WanDong Medical held its 13th meeting of the 10th Board of Directors, where Wang Jianguo was elected as the new chairman, succeeding Ma Chibing, who resigned for personal reasons [1][2]. - The first extraordinary general meeting of shareholders in 2026 was also held on January 26, where Wang Jianguo was elected as a non-independent director with 98.3021% of the votes in favor [2]. - The Board's strategic committee has been adjusted to include Wang Jianguo, Song Jinsong, Zhong Zheng, and Liu Xiao, with Wang Jianguo serving as the convener [2].